PMID- 8376779
OWN - NLM
STAT- MEDLINE
DCOM- 19931020
LR  - 20071114
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 151
IP  - 6
DP  - 1993 Sep 15
TI  - Neutrophil attractant protein-1 and monocyte chemoattractant protein-1 in human 
      serum. Effects of intravenous lipopolysaccharide on free attractants, specific 
      IgG autoantibodies and immune complexes.
PG  - 3292-8
AB  - We recently found that normal human sera contain IgG antibodies against two 
      chemoattractants, neutrophil attractant protein-1 (NAP-1/IL-8) and monocyte 
      chemoattractant protein-1 (MCP-1), as well as immune complexes of these proteins. 
      Intravenously administered LPS was reported to cause a sharp rise in serum NAP-1 
      concentration. Our study was designed to determine if LPS also caused an increase 
      in MCP-1 and to measure associated changes in concentrations of antibody and 
      immune complex. LPS caused a rise to peak within 2 to 3 h in serum concentrations 
      of free NAP-1 and MCP-1, followed by an almost equally rapid fall toward 
      base-line levels by about 5 h postinjection. MCP-1 concentration in sera from the 
      11 subjects rose to a peak of 330 +/- 52 pM. The peak value for NAP-1 was 80 +/- 
      11 pM. In 10 of the 11 subjects, free IgG autoantibody to MCP-1 decreased from a 
      mean pre-LPS value of 1820 +/- 660 pM to a mean low of 53% of the respective 
      initial values. Corresponding data for IgG anti-NAP-1 were a pre-LPS 
      concentration of 216 +/- 7 pM, which decreased to a mean low of 44% of the 
      respective initial values. The finding in some subjects of a rapid rise in free 
      antibody after the nadir suggests the possibility of acute regulation of 
      autoantibody secretion rates. Although the results suggested that LPS-induced 
      chemoattractant combined with free antibody, serum concentrations of MCP-1-IgG or 
      NAP-1-IgG did not increase, which points to an as yet unknown mechanism for 
      trapping and elimination of the immune complexes.
FAU - Sylvester, I
AU  - Sylvester I
AD  - Biological Carcinogenesis and Development Program, Program Resources, 
      Inc./DynCorp, National Cancer Institute-Frederick Cancer Research and Development 
      Center, MD.
FAU - Suffredini, A F
AU  - Suffredini AF
FAU - Boujoukos, A J
AU  - Boujoukos AJ
FAU - Martich, G D
AU  - Martich GD
FAU - Danner, R L
AU  - Danner RL
FAU - Yoshimura, T
AU  - Yoshimura T
FAU - Leonard, E J
AU  - Leonard EJ
LA  - eng
GR  - N01-CO-74102/CO/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Autoantibodies)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemotactic Factors)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin-8)
RN  - 0 (Lipopolysaccharides)
SB  - IM
MH  - Adult
MH  - Antigen-Antibody Complex/*metabolism
MH  - Autoantibodies/*blood
MH  - Chemokine CCL2
MH  - Chemotactic Factors/*metabolism
MH  - Female
MH  - Homeostasis
MH  - Humans
MH  - Immunoglobulin G/metabolism
MH  - Interleukin-8/*blood
MH  - Lipopolysaccharides/*pharmacology
MH  - Male
EDAT- 1993/09/15 00:00
MHDA- 1993/09/15 00:01
CRDT- 1993/09/15 00:00
PHST- 1993/09/15 00:00 [pubmed]
PHST- 1993/09/15 00:01 [medline]
PHST- 1993/09/15 00:00 [entrez]
PST - ppublish
SO  - J Immunol. 1993 Sep 15;151(6):3292-8.